2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylacetamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylacetamide
• 化学式: C₂₆H₂₇NO₂
• 分子量: 385.5
• InChiKey: YCBRYSUCQMSBDL-LCUIJRPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• THERAPEUTIC PHARMACEUTICAL COMPOSITION EMPLOYING ANTI-SLC6A6 ANTIBODY
  申请人：Order-Made Medical Research Inc.

  公开号：EP3095462A1

  公开（公告）日：2016-11-23

  The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.

  本发明旨在提供一种用于癌症治疗的药物组合物，该药物组合物包括与SLC6A6或其细胞外区域结合的新型单克隆抗体和与之结合的化疗剂，以及一种治疗方法，在该方法中，该单克隆抗体或由与化疗剂结合的单克隆抗体组成的治疗剂与化疗剂联合使用。本发明提供了一种药物组合物，该药物组合物包含一种抗体共轭物，该抗体共轭物是这样配置的：具有比传统抗体更高的亲和力并能识别原生 SLC6A6 或 SLC6A6 胞外区的原生多肽的单克隆抗体与具有抗癌和其他高增殖疾病活性的抗癌剂等共轭。
• CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY
  申请人：Order-Made Medical Research Inc.

  公开号：EP3441465A1

  公开（公告）日：2019-02-13

  The present invention aims to provide a cancer-specific new pharmaceutical composition with fewer side effects. The present invention provides a pharmaceutical composition comprising a monoclonal antibody recognizing a polypeptide of an extracellular region of native MCT5.

  本发明旨在提供一种副作用较少的癌症特异性新药物组合物。 本发明提供了一种药物组合物，它包含一种识别原生 MCT5 胞外区多肽的单克隆抗体。